EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Why Do Pharma Construction Projects Need Cost Certainty | Linesight | ISPE Singapore 2026 | Pharma Focus Asia
Associate Director, Project Controls, Linesight
Stephanie Ledwidge is an experienced project controls and cost management professional with expertise across the life sciences and pharmaceutical sectors She currently serves as Associate Director Project Controls at Linesight in Singapore Her experience spans project controls cost engineering project coordination and project delivery with previous roles supporting organisations including CSL Behr...
Articles
Homeopathic Science
Homeopathy a controversial medical system discovered by a German physician Samuel Hahnemann was first postulated at the end of the th century and mentioned in the first edition of his Organon in In such anecdotal times where theories about the deficiency four bodily fluids theories about corrupted juices were propagating against all odds the beginning of prescientific medical theories were bo...
Research Insights
Electrochemical studies for the determination of an antibiotic drug, D-cycloserine, in pharmaceutical and human biological samples
Abstract An antibiotic drug Dcycloserine CYS in phosphate buffer at different pH values was electrochemically studied using a gold electrode A wellresolved irreversible diffusioncontrolled voltammetric peak was obtained at V in a pH phosphate buffer solution with an ionic strength of M The experimental conditions such as the solution pH
Case Studies
Variation In Adverse Drug Reactions Listed In Product Information For Antidepressants And Anticonvulsants, Between The Usa And Europe: A Comparison Review Of Paired Regulatory Documents
Abstract Objective To compare consistency of adverse drug reaction ADR data in publicly available product information documents for brand drugs between the USA and Europe and to assess the usefulness of information for prescribers and patients Design A comparison review of product info
Techno Trends
Pear Therapeutics Developed reSET-A™ PDT Product Candidate for Alcohol Use Disorder (AUD)
Pear therapeutics developed new reSETA PDT product candidate for the treatment of alcohol use disorder AUD PDTsare new therapeutic class designed with software to directly treat disease Similar to traditional medicines PDTs are developed and tested
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Rethinking How Medicines Work
Dr. Asawari Pagare is a bioinformatician at UW Medicine where she studies the genomics of myositis, an autoimmune disease that is not yet well understood. She earned her PhD in Chemistry from the University of North Carolina at Chapel Hill, USA, where she explored how timing and fluctuations influence how living systems interpret signals relevant to medicine.
Determinants of Antimicrobial Resistance (AMR) Research in South East Asia
Raja Chakraverty is a serving Scientist with the Indian Council of Medical Research with a decade long research and teaching career in Pharmaceutical Sciences with 54 publications (186 citations) and a book
Doctoral Scholar, Department of Pharmaceutical Technology
M&A, Partnerships & Ecosystem Models in Biopharma
Surbhi Gupta is an Industry Principal at Frost & Sullivan with extensive experience in global pharmaceutical and biotech market research and consulting. She leads the Biopharma Therapeutics program, focusing on next-generation modalities and precision medicine. Her work spans market analytics, forecasting, competitive benchmarking, and strategy support for biopharma clients globally.
The Role of Technology in Continued Process Verification 4.0
Dr. Kavita is a seasoned leader in the field of data and insights, with over 20 years of invaluable experience. She is a result-oriented solution designer in data warehouse and big data analytics. Drawing from her extensive in multinational organisations IBM, Capgemini, and others, Kavita has successfully overseen numerous large and intricate projects. Her expertise lies in effectively leveraging her robust technical knowledge in areas such as data warehousing and business intelligence to drive impactful outcomes. Under Dr. Kavita's exceptional leadership, the CaliberAPQR product has achieved outstanding recognition.
Novel Developments in Drug Delivery Systems
Saina Bijanzadeh is a chemist specializing in nanomaterial-based drug delivery and biomedical applications. She has research experience in nanoparticle synthesis, MOF platforms, and drug release systems, with published work in international journals. Her interests focus on innovative therapeutic delivery strategies and interdisciplinary pharmaceutical and bio(medical)engineering research.
press releasesRead more...
Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Waters Corporation announced that it has launched Waters AI Link a software capability that brings Anthropics Model Context Protocol MCP to its informatics platform and has joined Anthropics Model Hardware Standard MHS research program
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda announced that ORZEYFUL oveporexton is now available in Japan and China for the treatment of narcolepsy type NT providing first access to clinicians to prescribe treatment with the new class of medicine ORZEYFUL is a firstinclass orexin receptor OXR agonist in tablet form designed to treat...
Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus
Merck known as MSD outside of the United States and Canada today inaugurated its stateoftheart ADVANCE research facility on its West Point Pennsylvania campus signaling a new chapter in global scientific discovery Pennsylvania Gov Josh Shapiro joined Merck executive leadership federal and state gove...
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
Alvotech a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited a global pharmaceutical company with a strategic focus on specialty hospital and rare disease medicines today announced the submissi...
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals Inc a global commercialstage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases today announced the commercial launch of IMCIVREE setmelanotide in Japan to treat patients living with acquired hypothalamic obesity HO...
Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement
Scinai Immunotherapeutics Ltd a biopharmaceutical company operating a growing contract development and manufacturing organization CDMO alongside an immunologyfocused therapeutic development platform today announced that its wholly owned subsidiary Scinai Biopharma Services Ltd has entered into a def...
EventsRead more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
LATEST NEWSRead more...
Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ
Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals
Vir Biotechnology Enters into Collaboration with Gilead Sciences to Develop T-cell Engagers for Solid Tumours
Vir Biotechnology has entered into a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel Tcell engager TCE candidates for the treatment of solid tumours Tcell engagers are designed to direct T cells a type of immune cell towards cancer cells and help destro...
Zealand Pharma Enters into Collaboration with Generate Biomedicines on AI-Designed Protein Therapies for Metabolic Diseases
Zealand Pharma and Generate Biomedicines have entered into a multitarget collaboration and licensing agreement to develop proteinbased treatments for obesity and other metabolic diseases using artificial intelligence AI The collaboration will combine Zealand Pharmas expertise in metabolic diseases w...
Enodia Therapeutics Enters into Collaboration with Pfizer to Develop Small-Molecule Sec61 Inhibitors
Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop smallmolecule inhibitors targeting Sec a protein complex involved in the movement of newly formed proteins across cell membranes
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases announced today that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has approved its Investigational New Drug IND application for ICPB a bispeci...
Mint Pharmaceuticals and Bayer Expand Medicine Distribution in Canada
Mint Pharmaceuticals and Bayer have expanded their distribution partnership in Canada to include several additional medicines across womens health cardiovascular care and anticoagulation